Amgen to acquire Rodeo Therapeutics in $721m worth deal
Amgen has agreed to acquire Rodeo Therapeutics, a Seattle-based biopharma company, in a deal worth up to $721 million. Rodeo Therapeutics is engaged in developing small-molecule therapies designed for promoting regeneration and repairing of multiple tissues. The company’s lead 15-prostaglandin dehydrogenase (15-PGDH) modulators have produced compelling data in extensive preclinical studies and have clinical potential […]